CTMI Cti Molecular Imaging - Common Stock (MM)

Mirada Solutions Presents New Software Capabilities for Drug Discovery and Development With PET OXFORD, England, June 24 /PRNewswire/ -- Mirada Solutions Ltd. (a subsidiary of CTI Molecular Imaging, Inc. (NASDAQ:CTMI)), leaders in software for molecular imaging, announced today that they have expanded their image analysis software offerings to include functionality specifically targeted at biomedical research. Imaging plays an increasingly important role in drug discovery and development, allowing the non-invasive study of the biology of disease, pharmacokinetics and dynamics of novel therapies. New R&D extensions to Mirada's OEM and workstation products enable researchers to import and analyze images from different modalities, different vendor's equipment and different species onto a single platform. Previously this has been difficult to achieve due to the wide variety of data formats used in small imaging systems as well as limited support for dynamic studies. Systems supported include Concorde Microsystems, ImTek, Bruker, Philips and others. Central to these new tools are an advanced multi-modality engine capable of temporal imaging, motion correction and image fusion, including software interface support for users to build their own algorithms into the environment. Although highly optimized for PET and PET/CT, the software is also designed to support other dynamic/functional modalities such as MRI. Quantification tools for dynamic imaging and bio-distribution analysis are also incorporated into the solution. Clare F. Jones Ph.D, Vice President of Marketing at Mirada explained, "Mirada Solutions has recognized the need to integrate studies from different systems. Our platform will allow information from different modalities to be analyzed longitudinally and facilitate translational research with a core focus on quantification, an extremely powerful capability for pharmaceutical research. Furthermore, Mirada's image analysis architecture utilizes a database environment that makes it easy to manage imaging information created as part of a multi-center clinical trial. Facilitating drug discovery and development is a key focus of the CTI family of companies and software is an increasingly important part of this activity." About Mirada Solutions: Mirada Solutions Limited, a wholly owned subsidiary of CTI Molecular Imaging, is a leading developer of software and analytical tools for medical imaging workstations, OEM imaging platforms and pharmaceutical research. Mirada's unique products aid in better detection, diagnosis and management of disease through the application of powerful algorithms, quantification tools and image analysis. Additional information is available at http://www.mirada-solutions.com/ . About CTI Molecular Imaging: CTI Molecular Imaging, Inc. is a leading supplier of products and services for positron emission tomography (PET), a diagnostic imaging technology used in the detection and treatment of cancer, cardiac disease and neurological disorders. Additional information is available at: http://www.ctimi.com/ Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as "believe," "assume," "expect," "anticipate," "intend," "estimate" or similar expressions, and any other statements that necessarily depend on future events. Forward-looking statements involve a number of risks and uncertainties and there can be no assurance that any forward-looking statements will prove to be accurate. Various factors could cause actual results to differ materially from those anticipated in the forward-looking statements. CTI undertakes no obligation to update or revise any forward- looking statements. Further information regarding risks, uncertainties and other factors that could adversely affect CTI or cause actual results to differ materially from those anticipated in forward-looking statements are included in CTI's Annual Report on Form 10-K for the fiscal year ended September 30, 2003, Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. DATASOURCE: Mirada Solutions Ltd. CONTACT: Clare F. Jones of Mirada Solutions Ltd., +44 1865 265 500; or Michael A. Lawless, CTI Molecular Imaging, Inc., +1-865-218-2000 Web site: http//:http://www.mirada-solutions.com/ http//:http://www.ctimi.com/

Copyright